Vaccine sales are expected to fade after a Q1 pop at AstraZeneca, but a slate of successful franchises buoys forecast
All the pistons driving revenue growth were pumping during AstraZeneca’s Q1, with Alexion contributing to strong performance in the Big Pharma’s swelling oncology business. But there’s one new contributor that AstraZeneca CEO Pascal Soriot says is headed for a fall.
Their Covid-19 vaccine franchise — hammered early by some fleeting concerns about a rare side effect — registered more than a billion dollars in sales in Q1, with Evusheld contributing an additional $469 million. But even as Evusheld sales are expected to grow, the vaccine sales are expected to diminish as the world has flipped from a scarcity of pandemic vaccines to a glut.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.